FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to novel imidazo[1,2-a]pyridine derivatives of general formula (I) or to its stereochemical isomeric forms, or to its pharmaceutically acceptable salts, where R1 represents C1-6alkyl; C3-6cycloalkyl; trifluoromethyl; C1-3alkyl, substituted with trifluoromethyl, C3-7cycloalkyl, phenyl; phenyl, substituted with 2 substituents, selected from group, consisting of halogeno; R2 represents cyano, halogeno or C1-3alkyl; R3 represents radical of formula (a), or (b), or (d); R4 represents hydroxyC3-6cycloalkyl; pyridinyl, substituted with one C1-3alkyl group; pyrimidinyl; pyrimidinyl, substituted with two C1-3alkyl groups; phenyl; phenyl, substituted with 1 or 2 substituents, selected from group, consisting of halogeno, hydroxyC1-3alkyl, mono- or polyhalogenoC1-3alkyl, C1-3alkyloxy and monohalogeno- C1-3alkyloxy; R5 represents hydrogen, fluoro, hydroxyl or monopholinyl; X represents C or N, with R5 representing electron pair on N; or R4-X-R5 represents radical of formula (i), or (j), or (k); n equals 0 or 1' q equals 1 or 2; R6 represents C1-3alkyl; C3-6cycloalkyl; hydroxyC2-4alkyl; (C3-6cycloalkyl)C1-3alkyl; phenyl; or phenyl, or pyridinyl, substituted with one substituent, selected from group, consisting of halogeno, C1-3alkyl and (CH2)m-CO2H, where m equals 0; or R6 represents cyclic radical of formula (l); where R8 represents hydrogen, p equals 2; Z represents O or CR9(OH), where R9 represents hydrogen or C1-3alkyl; R7 represents hydrogen or halogeno; Y represents covalent bond, O, NH, S, C(OH)(CH3), -CH2-O-, -O-CH2-, CHF or CF2; or R6-Y represents morpholinyl, pyrrolidinyl or piperidinyl, possibly substituted with hydroxyl or hydroxyC1-3alkyl; and A represents O or NH. Invention also relates to pharmaceutical composition based on formula (I), its application and method of treatment or prevention of central nervous system disorders.
EFFECT: novel imidazo[1,2-a]pyridine derivatives, which possess activity of positive allosteric mGluR2 modulator are obtained.
21 cl, 3 tbl, 22 ex
Title | Year | Author | Number |
---|---|---|---|
NEW SUBSTITUTED DIASASPIROPYRIDINE DERIVATIVES APPLIED IN TREATING MCH-1-MEDIATED DISEASES | 2007 |
|
RU2461558C2 |
3-AZABICYCLO[3,1,0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2510396C2 |
INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2512283C2 |
PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES | 2005 |
|
RU2367663C2 |
USING SIP RECEPTOR MODULATOR | 2008 |
|
RU2498796C2 |
CYCLOPROPYLPIPERIDINE GLYCINE TRANSPORTER INHIBITORS | 2005 |
|
RU2387644C2 |
2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS LEUCINE-RICH REPEAT KINASE 2 (LRRK2) MODULATORS FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2661197C2 |
DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS CONTAINING THEM, OBTAINING AND APPLICATION | 2004 |
|
RU2346938C2 |
DERIVATIVES OF PYRIMIDINE SULFONAMIDE AS MODULATORS OF CHEMOKINE RECEPTORS | 2005 |
|
RU2408587C2 |
INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2517181C2 |
Authors
Dates
2013-09-10—Published
2008-11-12—Filed